Díaz Luis A, Mortensen Eric M, Anzueto Antonio, Restrepo Marcos I
Geisinger Health System and Fundación Universitaria de Ciencias de la Salud, Hospital de San José, Bogotá DC, Colombia.
Ther Adv Respir Dis. 2008 Dec;2(6):387-400. doi: 10.1177/1753465808098694.
Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the US. It accounts each year for 500,000 hospitalizations and 45,000 deaths and represents one of the most common causes of intensive care unit (ICU) admission. The mortality rate due to severe CAP has shown little improvement in the past three decades, remaining between 21% and 58% in patients admitted to the intensive care unit. Antimicrobial agents are the cornerstone of therapy against CAP, but there are some novel antibiotic and nonantibiotic therapies that have been recently tested that may potentially impact outcomes of patients with severe CAP. We will review the most recent data regarding novel therapies in patients with the highest risk of death such as those with severe CAP.
社区获得性肺炎（CAP）是美国感染性疾病致死的首要原因。每年有50万人因之住院，4.5万人死亡，是重症监护病房（ICU）收治的最常见病因之一。在过去三十年里，重症CAP的死亡率几乎没有改善，入住重症监护病房的患者死亡率仍在21%至58%之间。抗菌药物是治疗CAP的基石，但最近测试了一些新型抗生素和非抗生素疗法，它们可能会影响重症CAP患者的治疗结果。我们将回顾关于死亡风险最高的患者（如重症CAP患者）新型疗法的最新数据。
